1 min read
Add as a preferred source on Google

Bernstein Downgrades Summit Therapeutics to Underperform on R&D Concerns

The FDA declined to approve ivonescimab, Summit’s lead asset developed with partner Akeso in China.

An unmarked vial sits behind a glass partition in a sterile lab / TokenPost.ai
An unmarked vial sits behind a glass partition in a sterile lab / TokenPost.ai

Bernstein lowered its rating on Summit Therapeutics Inc. (NASDAQ: SMMT) to Underperform from Market Perform on Nov. 18, citing concern about the company’s research and development capabilities after the FDA declined to approve its lead asset, ivonescimab.

Summit developed ivonescimab with partner Akeso in China.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…